Epilepsy surgery in Neurofibromatosis Type 1

Area of Science:

• Neurology
• Neurosurgery
• Genetics

Background:

• Epilepsy is uncommon in Neurofibromatosis Type 1 (NF1), usually responding to medication.
• Drug-resistant epilepsy can occur in NF1, especially with cortical malformations or tumors.
• Limited data exists on epilepsy surgery outcomes for NF1 patients.

Purpose of the Study:

• To evaluate the effectiveness of epilepsy surgery in patients with Neurofibromatosis Type 1 and drug-resistant seizures.
• To identify factors influencing surgical outcomes in this patient population.

Main Methods:

• A survey of 25 European epilepsy surgery centers identified 12 NF1 patients who underwent surgery for drug-resistant seizures.
• Patient data included MRI findings, seizure origin, surgical procedure, histology, and postoperative outcomes.
• Outcomes were assessed at 1, 2, and 5 years post-surgery.

Main Results:

• 11 of 12 patients had MRI abnormalities, with most seizures originating from the temporal lobe.
• Eight patients (67%) were seizure-free one year after surgery; outcomes remained stable for most at 2 and 5 years.
• Histology revealed dysembryoplastic neuroepithelial tumors (DNETs) in 5 patients, suggesting a potential association with NF1.

Conclusions:

• Epilepsy surgery is effective in NF1 patients with a single, identifiable epileptogenic zone.
• The high rate of DNETs in this cohort warrants further investigation into their association with NF1.
• Surgery offers a viable treatment option for refractory epilepsy in NF1.